NOTE TO READERS: When this project lost substantial funding at the end of 2018, I lost the ability to continue publishing criteria-driven news story reviews and PR news release reviews - once the bread-and-butter of the site going back to 2006. The 3,200 archived reviews, while still educational, are getting old and difficult for me to technically maintain on the back end of the website. So I am announcing that I plan to remove these reviews from the site by April 1, 2021. The blog and the toolkit - two of the most popular features on the site - will remain. If you wish to peruse the reviews before they disappear, please do so by the end of March 2021. After that date you may still be able to access them via the Internet Archive Wayback Machine - https://archive.org/web/.

Categories: diabetes

4/20/2018

Announcement advocating increased screenings for diabetes ignores harms of overdiagnosis

3 11/22/2016

Device for type 2 diabetes: Release prematurely touts benefits from 60-person study

11/10/2016

Weight Watchers for type 2 diabetes: PR release left out researchers’ many financial ties to the corporation

9/2/2016

Metformin ‘could slow development of heart disease’ in type 1 diabetes? Release vastly overstates what small study can tell us.

5/23/2016

PR release on oral insulin pill opened door to questions about benefits, evidence

2 3/25/2016

Exaggeration found in PR release claim that anyone can “reverse” their Type 2 diabetes

3/2/2016

Exemplary explanation of study comparing diabetic macular edema treatments

11/19/2015

Generally strong description of diabetic retinopathy drug trial — but more transparency please

5/1/2015

Does sleep apnea treatment really “lower diabetes risk”? This news release oversells the evidence